Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical
treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with
type 2 Diabetes (DM2). Investigators also hope to show that successful RYGB will reduce
resource utilization in the near term with similar projected reduction over the medium to
long term.